


**Hold**

(old: Hold)

Risk:  
medium**Target:** 15,00 €**Strong Q1**

|            |                |          |         |
|------------|----------------|----------|---------|
| Bloomberg: | DE0005104400   | Price:   | 16,90 € |
| Reuters:   | AOFG.DE        | Tech-AS: | 935,75  |
| ISIN:      | AOF            |          |         |
| Internet:  | www.ATOSS.com  |          |         |
| Segment:   | Prime Standard |          |         |
| Sector:    | Software/IT    |          |         |



Price data: Bloomberg

26.04.2006 / closing price

High / Low 52 W: 19,00 € / 7,80 €  
 Market capitalisation: 68,04 €m  
 No. of shares: 4,03 million

Shareholders: Free float 40,0%  
 Founders family 54,9%  
 Own shares 5,1%

Calendar: AGM 02.05.2006  
 Figures Q1/06 25.05.2006  
 Figures Q2/06 23.08.2006

**Analysis: SES Research**

Published: 27.04.2006  
 Felix Ellmann (Analyst) +49-(0)40 309537-12

**Institutional Client Contact: M.M.Warburg & CO**

Barbara C. Effler (Head of Equities) +49-(0)40 3282-2636

**Institutional Equity Sales**

Rainer Jell (Head of Sales) +49-(0)40 3282-2630

Ann-Katrin Gross +49-(0)40 3282-2635

Dr. James F. Jackson +49-(0)40 3282-2664

Marina Konzog +49-(0)40 3282-2669

Wolf Mandt-Merck +49-(0)40 3282-2666

Dirk Rosenfelder +49-(0)40 3282-2692

Steffen Schier +49-(0)40 3282-2665

Andreas Wessel +49-(0)40 3282-2663

**Sales Trading**

Gudrun Bölsen +49-(0)40 3282-2679

Oliver Merckel +49-(0)40 3282-2634

Tobias Rothaler +49-(0)40 3282-2701

Thekla Struve +49-(0)40 3282-2668

**Sales Assistance**

Wiebke Möller +49-(0)40 3282-2703

Kerstin Muthig +49-(0)40 3282-2632

Atoss Software AG announced the figures for Q1 2006 on 27th April 2006. The figures were in line with expectations (see table), but it must be mentioned that the figures include an extraordinary effect in a size of +0,4 €m). This effect is caused by the selling of AENEIS (please also read our News-Flash dated 23.12.06).

|                           | Q1 2006     |             |        |       |
|---------------------------|-------------|-------------|--------|-------|
|                           | reported    | prognosis   | delta  | Y-o-Y |
| <b>Sales</b>              | <b>5,12</b> | <b>5,15</b> | -0,64% | 5,0   |
| <b>EBITDA</b>             | <b>0,81</b> | <b>0,87</b> | -6,78% | 0,2   |
| Margin                    | -           | 16,89%      |        | 3,42% |
| <b>EBIT</b>               | <b>0,71</b> | <b>0,66</b> | 6,97%  | 0,0   |
| Margin                    | -           | 12,82%      |        | n.m.  |
| <b>Net income</b>         | <b>0,50</b> | <b>0,46</b> | 8,04%  | 0,0   |
| Margin                    | -           | 8,93%       |        | n.m.  |
| <b>EpS</b>                | <b>0,13</b> | <b>0,11</b> | 18,18% | 0,00  |
| EpS in €, all other in €m |             |             |        |       |

Table 1; source: ATOSS, SES Research

The crucial point of today's figures was yet the outlook. The company plans to achieve an EBIT-margin of at least 8% respectively an EBIT of 1,7 €m.

| End fiscal year                           | 12/05  | 12/06e | 12/07e | 12/08e | CAGR  |
|---|--------|--------|--------|--------|-------|
| <b>Sales</b>                              | 20,4   | 21,6   | 23,5   | 25,5   | 7,7%  |
| Sales (old)                               |        | 21,4   | 23,2   |        | -     |
| Delta                                     |        | 0,9%   | 1,1%   |        |       |
| <b>EBITDA</b>                             | 1,2    | 2,9    | 3,4    | 4,1    | 51,1% |
| Margin                                    | 5,83%  | 13,43% | 14,52% | 16,07% |       |
| EBITDA (old)                              |        | 2,3    | 3,1    |        | -     |
| Delta                                     |        | 26,1%  | 9,9%   |        | n.a.  |
| <b>EBIT</b>                               | 0,6    | 2,0    | 2,5    | 3,1    | 76,0% |
| Margin                                    | 2,77%  | 9,43%  | 10,52% | 12,07% |       |
| EBIT (old)                                |        | 1,5    | 2,2    |        | -     |
| Delta                                     |        | 35,8%  | 12,2%  |        | n.a.  |
| <b>Net income</b>                         | 0,5    | 1,3    | 1,5    | 1,9    | 59,7% |
| Marge                                     | 2,23%  | 6,07%  | 6,41%  | 7,26%  |       |
| Net income (old)                          |        | 1,0    | 1,3    |        | -     |
| Delta                                     |        | 31,2%  | 15,6%  |        | n.a.  |
| <b>EpS</b>                                | 0,11   | 0,32   | 0,37   | 0,45   | 59,2% |
| EpS (old)                                 |        | 0,24   | 0,31   |        | -     |
| Delta                                     |        | 34,3%  | 18,8%  |        | n.a.  |
| <b>Dividend</b>                           | 0,11   | 5,50   | 0,13   | 0,16   | 12,9% |
| Yield                                     | 0,65%  | 32,54% | 0,76%  | 0,94%  |       |
| Dividend (old)                            |        | 5,50   | 0,10   | 0,13   |       |
| Delta                                     |        | 0,0%   | 31,8%  | 26,2%  |       |
| EpS in €, all other in €m, price: 16,90 € |        |        |        |        |       |
| <b>Price/SALES</b>                        | 3,36   | 3,18   | 2,93   | 2,69   |       |
| <b>PER</b>                                | 150,65 | 52,44  | 45,88  | 37,36  |       |
| <b>EV/Sales</b>                           | 2,03   | 1,92   | 1,76   | 1,62   |       |
| <b>EV/EBITDA</b>                          | 34,78  | 14,27  | 12,15  | 10,09  |       |

With this statement the company upped its own prognosis and also beat our expectations so far. The described one-off effect, a good utilisation ratio, and the acquisition of several new interesting customers makes us believe that the new guidance will rather describe the lower end of the companies possibilities. In this context the company also underlined its „conservative prognosis policy“.

ATOSS sees further potential arising from continuing the positive trend of the two recent quarters. The premium-market (higher end of the mid-size enterprise market and also major clients) could also continue to pick up speed. The ending personnel expenses from the staff participation programme will probably also have a positive effect on the earnings upon mid-term view.

We assume that the sales revenues will stay on an almost equal level despite the selling of the AENEIS software – but we believe that the result will be improved. Our prognoses are thus slightly more optimistic than the company guidance.

In this context we raise our price target to 15,00 € (respectively 9,50 € after payout). Our rating maintains at Hold Rating.

**Disclaimer:** The legal disclaimer as well as updated disclosures according to Section 34b of the German Securities Trading Act and German FinAnV on the security/securities analysed in this report can be found on internet pages at: <http://www.mmwarburg.com/research/disclaimer/disclaimer.htm> The disclaimer and disclosures provided are considered a part of this report and should be taken into account when making investment decisions based on this report.

**Copyright:** This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.